Navigation Links
30+ AIDS vaccine clinical trials in 24 countries, research occurring on every continent

The International AIDS Vaccine Initiative's (IAVI) January 2007 Annual Issue of VAX, an editorially independent bulletin on AIDS vaccine research published by IAVI, reports that 13 new preventive AIDS vaccine trials were initiated in eight countries around the world in 2006. There are now more than 30 trials ongoing in 24 countries, across every continent.

This annual publication provides the only comprehensive listing of all AIDS vaccine clinical trial activity worldwide.

Last year saw the start of the first AIDS vaccine trials in the Russian Federation and Zambia, and three countries in sub-Saharan Africa —Kenya, Uganda, and Tanzania—also initiated new trials. The United States, United Kingdom, Sweden and Peru began new trials in 2006 as well. Many of these trials were sponsored by new research groups, including the Karolinska Institute in Sweden, St. George's University of London and the Moscow Institute of Immunology.

All of the new trials that began last year were either Phase I or Phase I/II trials designed to evaluate the safety and immunogenicity of the candidate vaccines. "Although these new trials are early-stage, they will provide critical information over the coming years that will help drive the field's R&D agenda. We hope to begin to see even more novel vectors, as well as approaches that target neutralizing antibodies in the next few years," said CEO and President of IAVI, Dr. Seth Berkley.

IAVI and its collaborators are currently conducting four ongoing trials in India, Kenya, Rwanda, Uganda, South Africa and the United States. In 2006, IAVI launched a Phase II trial in Uganda and Zambia, part of a multi-site study that also included three sites in South Africa. The South Africa, Uganda and Zambia trial sites are now fully enrolled with data expected later this year.

Two of the most advanced trials underway in 2007 are from Sanofi-Pasteur and Merck & Co., Inc. Data from Merck's ongoing Phas
'"/>

Source:International AIDS Vaccine Initiative


Page: 1 2

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... from a mutation in one genome are complicated enough, ... genomes: the DNA in the nucleus and in the ... genomic disconnects cause disease. In a step in that ... traced one such incompatibility in fruit flies down to ...
... ten million, with dogs producing approximately 1,000 tonnes of excrement ... as a major source of the parasite egg, Toxocara ... humans. The aim of the study, led by Dr ... of Veterinary Sciences and published in the international scientific journal, ...
... Here,s another reason why you should include olive oil ... the Journal of Leukocyte Biology ... significantly reduces intestinal ischemia (restricted blood supply) and the ... returns). The compound, called "oleuropein aglycone," is the most ...
Cached Biology News:Mitochondrial mutations: When the cell's 2 genomes collide 2Mitochondrial mutations: When the cell's 2 genomes collide 3Caring for dogs to reduce spread of parasite eggs harmful to humans 2Olive oil component alleviates intestinal ischemia and reperfusion 2
(Date:5/21/2015)... PA (PRWEB) May 21, 2015 ... has joined the firm as senior statistician and Principal, ... years of experience in the management and analysis of ... pharmaceutical and chemical industries. , “We’re delighted to have ... capabilities in data analytics,” said Dr. Philippe Cini, Group ...
(Date:5/20/2015)... 2015 This year has been one ... US Patented Pearl’s Premium Ultra Low Maintenance Lawn ... country that are coming out of record bad weather. ... of major global concerns related to water, health, and ... the alternative to the standard, water-wasting, chemical-treated standard lawn. ...
(Date:5/20/2015)... 2015 The global genotyping market is ... the forecast period of 2015 to 2020 to reach ... in drug discovery and development process and to provide ... addition to this,heavy investments by key manufacturers to offer ... propelling market growth. Browse 113 market data tables & ...
(Date:5/20/2015)... 20, 2015  Marc Tessier-Lavigne, president of The ... $100 million from The Marie-Josée and Henry R. ... building that will be the centerpiece of the ... Henry R. Kravis Research Building, two stories high, ... approximately three city blocks following the shoreline of ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4
... for Bevasiranib Broadly Covers siRNA Targeting of, VEGF Expression, Further Strengthening ... ... MIAMI, March 18 OPKO Health, Inc. (Amex: OPK ),today announced ... and Trademark Office (USPTO) for methods related to the use and,administration of ...
... safety, effectiveness, and environmental impact of removing pollutant, ... ... products-, BOURNE, Mass., ... company has closed the first,tranche of a $2.5 million institutional financing ...
... Mich., March 18 Neogen Corporation,(Nasdaq: NEOG ) announces the following ... When: March 25, 2008 11:00 EDT, Where: ... Simply log on to the web at the address ... of Neogen Corporation, +1-800-234-5333. If you are unable to participate during ...
Cached Biology Technology:OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 2OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 3OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib 4Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 2Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 3Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing 4
... Adapted to Sf-900 II ... isolated from Spodoptera frugiperda ... cells (1). The Sf21 ... serum-free suspension culture in ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
MAGP-2 (C-19)...
... Immunogen: Synthetic peptide derived from ... junctophilin-2. Specificity: Specific for the ... controls: mouse skeletal muscle homogenates frozen ... Western blotting Immunohistochemistry(froz) ImmunofluorescenceStorage: Store at ...
Biology Products: